Cytomegalovirus colitis in a patient undergoing postoperative adjuvant chemotherapy for lung adenocarcinoma with uracil-tegafur

Hideyuki Hayashi, Yoshito Komatsu, Takumi Uchida, Nobuhiko Abe, Ken Ito, Kouji Hirata, Kana Matsuda, Akira Fujinaga

Research output: Contribution to journalArticlepeer-review

Abstract

When we examine a patient with symptoms of acute enteritis in the course of chemotherapy with oral fluoropyrimidines such as uracil-tegafur (often referred to as UFT), we usually suspect 5-fluorouracil-induced enterocolitis. In case of persistent clinical symptoms despite discontinuation of chemotherapy, cytomegalovirus colitis should be considered in the differential diagnosis of chemotherapy-induced enterocolitis. We herein report the case of a patient who underwent surgery for lung adenocarcinoma followed by postoperative adjuvant chemotherapy with uracil-tegafur and was diagnosed as having cytomegalovirus colitis during the therapy. In the course of chemotherapy, cytomegalovirus colitis occasionally occurs even though the patient does not experience severe myelosuppression; thus, it is necessary that we recognize its potential occurrence.

Original languageEnglish
Pages (from-to)826-829
Number of pages4
JournalJournal of Infection and Chemotherapy
Volume22
Issue number12
DOIs
Publication statusPublished - 2016 Dec 1

Keywords

  • 5-Fluorouracil-induced enterocolitis
  • Adverse effect
  • Chemotherapy
  • Cytomegalovirus colitis
  • Lymphopenia
  • Uracil-tegafur

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Cytomegalovirus colitis in a patient undergoing postoperative adjuvant chemotherapy for lung adenocarcinoma with uracil-tegafur'. Together they form a unique fingerprint.

Cite this